Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

Role of Corticotropin-Releasing Factor (CRF) Receptors in the Anorexic Syndrome Induced by CRF

Mary Ann Pelleymounter, Margaret Joppa, Michelle Carmouche, Mary Jane Cullen, Brock Brown, Brian Murphy, Dimitri E. Grigoriadis, Nick Ling and Alan C. Foster
Journal of Pharmacology and Experimental Therapeutics June 2000, 293 (3) 799-806;
Mary Ann Pelleymounter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margaret Joppa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Carmouche
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Jane Cullen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brock Brown
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Murphy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dimitri E. Grigoriadis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nick Ling
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan C. Foster
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Genetic manipulations of corticotropin-releasing factor (CRF)1 and CRF2 receptors have resulted in data suggesting that the CRF2 receptor could mediate the effects of CRF on appetite or satiety. We have attempted to obtain pharmacological evidence for this hypothesis by comparing the ability of a high-affinity peptide, mixed CRF antagonist [cyclo 30-33,f12,L18,21E30, A32,K33]sucker fish urotensin (12-41)NH2 [cUTSN (12-41)] with a small-molecule CRF1-selective antagonist, NBI-27914, and a CRF2-selective peptide antagonist, antisauvagine-30, to attenuate the anorexic effects of CRF. We also monitored other behaviors that accompanied CRF-induced anorexia. CRF-induced anorexia was significantly correlated with a reduction in locomotor activity and an increase in freezing behavior and piloerection. cUTSN (12-41) and antisauvagine-30 significantly attenuated the effects of CRF (0.04 nmol) on food intake along with the behavioral syndrome that accompanied anorexia. In contrast, NBI-27914 did not attenuate either of the above-mentioned CRF-induced phenomena when given centrally at doses ranging from 0.13 to 10 nmol/2.5 μl or when given orally at 20 to 40 mg/kg. Although these data support the hypothesis that the CRF2 receptor mediates the appetite suppression induced by CRF, they also suggest that the CRF2 receptor could mediate the stress-like behaviors that accompany CRF-induced appetite suppression.

Footnotes

  • Send reprint requests to: Mary Ann Pelleymounter, Neurocrine Biosciences, 10555 Science Center Dr., San Diego, CA 92121. E-mail: MPelleymounter{at}neurocrine.com

  • ↵1 This study was supported in part by Grant 1R44NS35410-02 funded through the Small Business Innovative Research program at the National Institutes of Health.

  • Abbreviations:
    CRF
    corticotropin-releasing factor
    UCN
    urocortin
    cUTSN (12-41)
    [cyclo 30-33,f12,L18,21E30,A32,K33]sucker fish urotensin (12-41)NH2
    • Received December 2, 1999.
    • Accepted March 9, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 293 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 293, Issue 3
1 Jun 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Role of Corticotropin-Releasing Factor (CRF) Receptors in the Anorexic Syndrome Induced by CRF
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

Role of Corticotropin-Releasing Factor (CRF) Receptors in the Anorexic Syndrome Induced by CRF

Mary Ann Pelleymounter, Margaret Joppa, Michelle Carmouche, Mary Jane Cullen, Brock Brown, Brian Murphy, Dimitri E. Grigoriadis, Nick Ling and Alan C. Foster
Journal of Pharmacology and Experimental Therapeutics June 1, 2000, 293 (3) 799-806;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNEUROPHARMACOLOGY

Role of Corticotropin-Releasing Factor (CRF) Receptors in the Anorexic Syndrome Induced by CRF

Mary Ann Pelleymounter, Margaret Joppa, Michelle Carmouche, Mary Jane Cullen, Brock Brown, Brian Murphy, Dimitri E. Grigoriadis, Nick Ling and Alan C. Foster
Journal of Pharmacology and Experimental Therapeutics June 1, 2000, 293 (3) 799-806;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Substituted Tryptamine Activity at 5-HT Receptors and SERT
  • KRM-II-81 Analogs
  • VTA muscarinic M5 receptors and effort-choice behavior
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics